Accepting or declining the offer of prenatal screening for congenital defects: Test uptake and women's reasons

Prenatal Diagnosis

Volumn 25, Issue 1, 2005, Pages 84-90

  Van Den Berg, Matthijs ^a,b   Timmermans, Danielle R M ^a   Kleinveld, Johanna H ^a   Garcia, Elisa ^a   Van Vugt, John M G ^b   Van Der Wal, Gerrit ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Decision making; Down syndrome; Prenatal screening; Reasons; Uptake

Indexed keywords

ABORTION; ANXIETY; ARTICLE; CONGENITAL MALFORMATION; DOWN SYNDROME; FETUS ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; MEDICAL DECISION MAKING; NETHERLANDS; PATIENT ATTITUDE; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY;

ABNORMALITIES; ADULT; DECISION MAKING; FEMALE; HUMANS; MASS SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT COMPLIANCE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; QUESTIONNAIRES;

EID: 13244278290     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1090     Document Type: Article

References (40)

1. Baillie C, Hewison J, Mason G. 1999. Should ultrasound scanning in pregnancy be routine? J Reprod Infant Psychol 17: 149-157.
2. Bekker HL, Hewison J, Thornton JG. 2003. Understanding why decision aids work: linking process with outcome. Patient Educ Couns 50: 323-329.
3. Benn PA. 2002. Advances in prenatal screening for Down syndrome: I. General principles and second trimester testing. Clin Chim Acta 323: 1-16.
4. Bennett MJ, Gau GS, Gau DW. 1980. Womens attitudes to screening for neural-tube defects. Br J Obstet Gynaecol 87: 370-371.
5. Berne-Fromell K, Josefson G, Kjessler B. 1984. Who declines from antenatal serum alpha-fetoprotein screening-and why? Acta Obstet Gynecol Scand 63: 687-691.
6. Browner CH, Press N. 1995. The normalisation of prenatal diagnostic screening. In Conceiving the New World Order: The Global Politics of Reproduction. Ginsburg FD, Rapp R (eds). University of California Press: Los Angeles; 307-322.
7. de Graaf IM, Tijmstra T, Bleker OP, van Lith JM. 2002. Womens' preference in Down syndrome screening. Prenat Diagn 22: 624-629.
8. Dormandy E, Hooper R, Michie S, Marteau TM. 2002a. Informed choice to undergo prenatal screening: a comparison of two hospitals conducting testing either as part of a routine visit or requiring a separate visit. J Med Screen 9: 109-114.
9. Dormandy E, Michie S, Weinman J, Marteau TM. 2002b. Variation in uptake of serum screening: the role of service delivery. Prenat Diagn 22: 67-69.
10. Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS. 2004. Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol Assess 8: 1-124.
11. Green JM, Statham H. 1996. Psychosocial aspects of prenatal screening and diagnosis. In The Troubled Helix: Social and Psychological Implications of the New Genetics. Marteau TM, Richards M (eds). Cambridge University Press: Cambridge; 140-163.
12. Health Council of the Netherlands: Committee on the Population Screening Act. 1996. Population screening act: the assessment of permit applications, 1996/09WBO. The Hague, Health Council of The Netherlands.
13. Health Council of the Netherlands: Committee on the Population Screening Act. 1999. Population screening act: prenatal screening and risk perception, 1999/04WBO. The Hague, Health Council of the Netherlands.
14. Health Council of the Netherlands. 2001. Prenatal screening: Down's syndrome, neural tube defects, routine-ultrasonography, 2001/11. The Hague, Health Council of the Netherlands.
15. Jorgensen FS. 1995a. Attitudes to prenatal screening, diagnosis and research among pregnant-women who accept or decline an alpha-fetoprotein test. Prenat Diagn 15: 419-429.
16. Jorgensen FS. 1995b. Declining an alpha-fetoprotein test in pregnancy, why and who? Acta Obstet Gynecol Scand 74: 3-11.
17. Kamerbeek LI, Roelofsen EE, Beekhuis JR, Tijmstra T, Mantingh A. 1993. How women cope with the results of maternal serum screening for fetal neural tube defects and Down syndrome? Ned Tijdschr Geneeskd 137: 1308-1311.
18. Kornman LH, Wortelboer MJ, Beekhuis JR, Morssink LP, Mantingh A. 1997. Women's opinions and the implications of first-versus second-trimester screening for fetal Down's syndrome. Prenat Diagn 17: 1011-1018.
19. Liamputtong P, Halliday JL, Warren R, Watson LF, Bell RJ. 2003. Why do women decline prenatal screening and diagnosis? Australian women's perspective. Women Health 37: 89-108.
20. Markens S, Browner CH, Press N. 1999. 'Because of the risks': how US pregnant women account for refusing prenatal screening. Soc Sci Med 49: 359-369.
21. Marteau TM, Dormandy E, Michie S. 2001. A measure of informed choice. Health Expect 4: 99-108.
22. Muller MA, Pajkrt E, Bilardo CM. 2002. Ultrasound screening for Down's syndrome early in pregnancy: nuchal translucency thickness. Ned Tijdschr Geneeskd 146: 793-798.
23. Nicolaides KH, Heath V, Cicero S. 2002. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 22: 308-315.
24. Pajkrt E, van Lith JMM, Mol BWJ, Bleker OP, Bilardo CM. 1998. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol 12: 163-169.
25. Press NA, Browner CH. 1993. Collective fictions-similarities in reasons for accepting maternal serum alpha-fetoprotein screening among women of diverse ethnic and social-class backgrounds. Fetal Diagn Ther 8: 97-106.
26. Press N, Browner CH. 1997. Why women say yes to prenatal diagnosis? Soc Sci Med 45: 979-989.
27. Press N, Browner CH. 1998. Characteristics of women who refuse an offer of prenatal diagnosis: Data from the California maternal serum alpha fetoprotein blood test experience. Am J Med Genet 78: 433-445.
28. Ritchie K, Boynton J, Bradbury I, et al. 2004. Routine ultrasound scanning before 24 weeks of pregnancy. Health Technology Assessment Report 5. NHS Quality Improvement Scotland: Glasgow.
29. Roelofsen EEC, Kamerbeek LI, Tymstra TJ. 1993. Chances and choices. Psycho-social consequences of maternal serum screening. A report from The Netherlands. J Reprod Infant Psychol 11: 41-47.
30. Salonen R, Ammala P. 1997. Prenatal diagnosis in Finland. Eur J Hum Genet 5: 22-25.
31. Sanden ML, Bjurulf P. 1988. Pregnant womens attitudes for accepting or declining a serum-alpha-fetoprotein test. Scand J Soc Med 16: 265-271.
32. Santalahti P, Aro AR, Hemminki E, Helenius H, Ryynanen M. 1998. On what grounds do women participate in prenatal screening? Prenat Diagn 18: 153-165.
33. Sher C, Romano-Zelekha O, Green MS, Shohat T. 2003. Factors affecting performance of prenatal genetic testing by Israeli Jewish women. Am J Med Genet Part A 120A: 418-422.
34. Smeenk ADJ, ten Have HAMJ. 2003. Medicalization and obstetric care: An analysis of developments in Dutch midwifery. Med Health Care Philos 6: 153-165.
35. Spencer K. 1999. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven year review. Br J Obstet Gynaecol 106: 1287-1293.
36. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. 2003. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. Br J Obstet Gynecol 110: 281-286.
37. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. 2000. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 107: 1271-1275.
38. Statistics Netherlands. 2004. Statistics Netherlands. www.cbs.nl. date of access: 23-03-2004.
39. Tymstra TJ, Bajema C, Beekhuis JR, Mantingh A. 1991. Women's opinions on the offer and use of prenatal diagnosis. Prenat Diagn 11: 893-898.
40. Weinans MJN, Huijssoon AMG, Tymstra T, Gerrits MCF, Beekhuis JR, Mantingh A. 2000. How women deal with the results of serum screening for Down syndrome in the second trimester of pregnancy? Prenat Diagn 20: 705-708.